TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* 18 years or greater~* Confirmed diagnosis of ACTH-dependent Cushing's disease~* Not considered candidate for pituitary surgery~Exclusion criteria~* History of pituitary irradiation in the last 10 years~* Cushing's syndrome not caused by pituitary tumor~* Patients with active malignant disease (cancer) in the last 5 years~* Women who are pregnant or lactating~Other protocol-defined inclusion/exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pasireotide 600 ug (Type: EXPERIMENTAL): At randomization, participants received 600 ug subcutaneously (sc) twice daily (bid). Participants continued at this dose until month 6 if their month 3 mean urinary free cortisol (mUFC) was \<= 2 x the upper limit of normal (ULN) and the mUFC was below or equal to their baseline mUFC. Participants not meeting the mUFC criteria at month 3 were unblinded and required to increase their dose to 900ug bid on an open label basis. Participants had the option to continue in the extension phase as long as they did not meet any discontinuation criteria or until pasireotide was available commercially in their country.
- Pasireotide 900 ug (Type: EXPERIMENTAL): At randomization, participants received 900 ug subcutaneously (sc) twice daily (bid). Participants continued at this dose until month 6 if their month 3 mean urinary free cortisol (mUFC) was \<= 2 x the upper limit of normal (ULN) and the mUFC was below or equal to their baseline mUFC. Participants not meeting the mUFC criteria at month 3 were unblinded and required to increase their dose to 1200 ug bid on an open label basis. Participants had the option to continue in the extension phase as long as they did not meet any discontinuation criteria or until pasireotide was available commercially in their country.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide in Overweight and Very Overweight Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have stable body weight for the past 1 month prior to screening~* Have a body mass index (BMI) between 27 to 50 kilograms per meter squared (kg/m²), inclusive at screening~* Willing and agreeable to commit to the duration of the study and undergo study procedures as instructed by the clinic staff~* Women must not be pregnant or breastfeeding~Exclusion Criteria:~* Have undergone or plan to undergo gastric bypass or bariatric surgery~* Have claustrophobia or have ferromagnetic implants that can interfere with completion of fMRI measurements~* Have other medical conditions or medical history that make participation in the study unsafe or which may interfere in the interpretation of the results of the study~* Unwilling to comply with smoking and alcohol restrictions during the study~* Have received prescription drugs or over the counter drugs that promote weight loss in the past 6 months prior to screening~* Have a diagnosis of type 2 diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tirzepatide (Type: EXPERIMENTAL): Participants received tirzepatide 5 milligrams (mg) once a week (QW) for Weeks 1 through 3 followed by tirzepatide 10 mg QW for Weeks 4 through 6 into the subcutaneous (SC) tissue of the abdominal wall.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered into the SC tissue of the abdominal wall.
- Liraglutide (Type: ACTIVE_COMPARATOR): Participants received Liraglutide with step wise dose escalation regimen starting from 0.6 mg once daily (QD) for week 1 followed by 1.2 mg QD for week 2, 1.8 mg QD for week 3, 2.4 mg QD for Week 4 followed by 3 mg QD starting in Week 5 and maintained for 10 days administered into the SC tissue of the abdominal wall.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older with diagnosis of plaque-type psoriasis (psoriasis vulgaris) for at least 12 months prior to first dose of study drug;~* Psoriasis Area and Severity Index (PASI) score of 12 or greater, AND Physician's Global Assessment (PGA) score of 3 (moderate) or 4 (severe); Psoriasis covering at least 10% of body surface area;~* No evidence of active or latent or inadequately treated infection with Tuberculosis or other serious infections.~Exclusion Criteria:~* Non-plaque or drug induced forms of psoriasis;~* Cannot discontinue current oral, injectable or topical therapy for psoriasis or cannot discontinue phototherapy (Psoralen Ultraviolet A; Ultraviolet B).~* Any uncontrolled significant medical condition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Treatment (10 mg) BID / Placebo BID (Type: EXPERIMENTAL): Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
- Active Treatment (10 mg) BID (Type: EXPERIMENTAL): Continuous active treatment (CP-690,550) for 56 weeks
- Active Treatment (5 mg) BID / Placebo BID (Type: EXPERIMENTAL): Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
- Active Treatment (5 mg) BID (Type: EXPERIMENTAL): Continuous active treatment (CP-690,550) for 56 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Tolerance and Equivalence of hCG-IBSA vs Recombinant Human Chorionic Gonadotrophin in Women Undergoing In Vitro Fertilisation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \>/=18 and \< 40 years old;~* BMI between 18 and 30 kg/m2;~* less than 3 previous completed cycles;~* both ovaries present;~* regular menstrual cycle of 25-35 days;~* infertility attributable to a tubal factor, American Fertility Society grade I or II endometriosis, male factor or unexplained factor.~* within 12 months of the beginning of the study, uterine cavity consistent with expected normal function as assessed through hysterosalpingogram, sonohystrogram or hysteroscopic examination;~* basal FSH level less than 10 IU/L;~* criteria for hCG administration fulfilled (at least 2 follicles with a diameter of 16 mm or more, with acceptable serum E2 concentration).~* a male partner with semen analysis within the past 6 months showing acceptable values of seminal parameters, defined as \> 3x10 exp 6 spermatozoa/ml;~* qualified to receive 150 - 300 IU FSH as starting dose.~Exclusion Criteria:~* age \< 18 and \> o = 40 years;~* primary ovarian failure or women known as poor responders (i.e. requiring more than 300 IU of FSH as a starting dose in previous treatment cycles or having less than 3 oocytes retrieved, or with an E2 serum concentration \< 3'000 pmol/L);~* ovarian cysts \> 20 mm, or enlargement not due to polycystic ovarian syndrome;~* patients affected by pathologies associated with any contraindication of being pregnant;~* hypersensitivity to the study medication;~* any bleeding since stimulation;~* uncontrolled thyroid or adrenal dysfunction;~* neoplasias;~* severe impairment of the renal and/or hepatic functions;~* use of concomitant medication that might interfere with study evaluations (e.g. nonstudy hormonal medications, prostaglandin inhibitors, psychotropic agents);~* more than 18 days of FSH stimulation.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Estradiol Levels in Patients Treated With Estring

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stage I-III estrogen receptor positive breast cancer (positive for estrogen receptor (ER)) with positivity defined as immunohistochemical staining in ≥ 10% of cells) on adjuvant hormonal therapy with aromatase inhibitors (anastrozole, letrozole or exemestane)~* Adults over 18 years of age with a life expectancy of at least 3 months~* Attained menopause as defined by World Health Organization Criteria (defined as permanent cessation of menstruation resulting from the loss of ovarian follicular activity. This is recognized to occur after 12 consecutive months of amenorrhea, for which there is no other obvious pathological or physiological cause.)~* Persistent genitourinary symptoms causing discomfort for more than 2 weeks prior to the visit with the physician.~* Tried at least 1 prior pharmacological/ non-pharmacological treatment for their genitourinary symptoms~* Be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to any study specific procedures~* Be willing and able to comply with the treatment plan, scheduled clinic visits, laboratory tests and other study procedures~Exclusion Criteria:~* Patients with metastatic breast cancer~* Have a concurrent active non-breast malignancy except for non-melanoma skin cancer~* Patients with vaginal stenosis~* Patients unable to apply Estring

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Estradiol (Type: EXPERIMENTAL): ESTRING® (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Head-to-head Comparison of Empagliflozin and Dapagliflozin

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Inadequately controlled under triple OADs (metformin, glimepiride, dipeptidyl peptidase inhibitor) as evidenced by HbA1c 7.5-12%~Exclusion Criteria:~* Type 1 diabetes~* Gestational diabetes~* Diabetes due to secondary causes~* Receiving anticancer treatment~* Receiving glucocorticoids or immune-suppressants~* have been treated with sodium-glucose co-transporter 2 inhibitors for more than 7 consecutive days within 3 months before entering this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Triple OADs failure (Type: None): Empagliflozin or dapagliflozin as an add-on drug for inadequately controlled T2D patients who are already receiving a regimen of three distinct OADs, including metformin, glimepiride and dipeptidyl peptidase 4 (DPP4) inhibitors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Analgesia in Knee Arthroscopic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for knee arthroscopy under spinal anaesthesia~Exclusion Criteria:~* Diabetes Mellitus~* Contraindication to spinal anesthesia~* Patient refusal

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: ACTIVE_COMPARATOR): patients will receive intra-articular 8 mg dexamethasone added to 18 mL 0.25% bupivacaine into the knee joint.
- Dexmedetomidine (Type: ACTIVE_COMPARATOR): patients will receive intra-articular 1ug/kg dexmedetomidine added to 18 mL 0.25% bupivacaine into the knee joint.
- Control (Type: PLACEBO_COMPARATOR): patients will receive intra-articular 18 mL 0.25% bupivacaine and 2mL isotonic saline into the knee joint.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Additional criteria check may apply for qualification:~* Glycated hemoglobin(HbA1c) of ≥6.5% and ≤12.0%~* eGFR of ≥30 mL/min/1.73m2 and \<90 mL/min/1.73m2~* The median UACR of the first morning void urine samples is ≥300 mg/g Cr and ≤5000 mg/g Cr~* Patients who are taking on angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)~* Patients who are under dietary management and taking therapeutic exercise for diabetes~Exclusion Criteria:~Additional criteria check may apply for qualification:~* Type I diabetes, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes~* A diagnosis of non-diabetic renal disease~* Hereditary glucose-galactose malabsorption or primary renal glucosuria~* Class IV heart failure symptoms according to New York Heart Association (NYHA) functional classification~* Severe hepatic disorder or severe renal disorder~* Blood potassium level \>5.5 mmoL/L~* Stable blood pressure (diastolic blood pressure (DBP) ≥100mmHg or systolic blood pressure (SBP) ≥180mmHg)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 100mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PNEUMOCELL - Conjugated Pneumococcal Vaccination in Patients With Immunoglobulin G-deficiency

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Immunoglobulin gamma-deficiency: Immunoglobulin gamma 1-deficiency \< 2,8 g/L and/or Immunoglobulin gamma 2-deficiency \< 1,15 g/L~* Age 18-65~Exclusion Criteria:~* Immunoglobulin gamma-substitution for 6 months prior to study inclusion~* Prevenar7 or Prevenar13 given prior to study inclusion.~* Pneumovax given during a 2 year period prior to study inclusion~* Pregnancy or planning to become pregnant during the study period (4 weeks)~* Taking part in another clinical study involving drugs or vaccinations during the study period (4 weeks).~* Taking systemic steroids, Non steroidal anti inflammatory drugs (NSAID) or immunosuppressive drugs.~* Being allergic to any substance in the vaccine.~* Acute and ongoing disease with high fever.~* Thrombocytopenia (\< 100x109/L).~* Coagulopathy~* Breastfeeding a baby~* The healthy controls should not have any disease with effects on the immune-system

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- IgG-deficient patients (Type: ACTIVE_COMPARATOR): Prevenar13
- Healthy controls (Type: ACTIVE_COMPARATOR): Prevenar13

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria.~* Post-pubovaginal sling patient.~* Complete agreement and signing of Informed Consent Form.~Exclusion Criteria.~* Currently taking antimuscarinics or α1 blockers.~* Patients with urinary retention, dependent on dialysis, gastroparesis or narrow angle glaucoma.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pubovaginal sling procedure (Type: EXPERIMENTAL): Patients undergoing pubovaginal slings for stress urinary incontinence.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose-ranging Study of Fluticasone Furoate (FF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent from at least one parent/ legal guardian to take part in the study.:~* Diagnosis of asthma~* pre-bronchodilator PEF between ≥50% to ≤90% of their best post-bronchodilator value~* Receiving therapy of short acting beta-agonist (SABA) alone, LTM, or ICS (total daily dose \<FP 200mcg or equivalent)Exclusion :~Exclusion Criteria:~* history of life-threatening asthma~* history of asthma exacerbation for asthma within 6 months prior to screening.~* Culture-documented or suspected bacterial or viral infection~* significant abnormality or medical condition~* Present use of any tobacco products

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): Fluticasone Furoate 100mcg inhalation powder once daily in the evening ICS powder
- Arm 2 (Type: ACTIVE_COMPARATOR): Fluticasone Furoate 50mcg inhalation powder once daily in the evening ICS powder
- Arm 3 (Type: ACTIVE_COMPARATOR): Fluticasone Furoate 25mcg inhalation powder once daily in the evening ics powder
- Arm 4 (Type: ACTIVE_COMPARATOR): Fluticasone Propionate 100mcg inhalation powder twice daily ICS powder
- Arm 5 (Type: PLACEBO_COMPARATOR): Placebo inhalation powder once daily in the evening Placebo powder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of LacTEST for the Diagnosis of Hypolactasia in Adults and Elderly Patients Presenting With Clinical Symptoms of Lactose Intolerance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults of either sex, between 18 and 70 years old.~2. Capacity for understanding and giving the informed consent to participate in this study.~3. Patients with clinical suggestive of lactose intolerance, primary or secondary, who have not been diagnosed and that fulfil the requirements allowed by the gaxilose summary of product characteristics (SmPC).~Exclusion Criteria:~1. Pregnant women or breast-feeding women.~2. Unable or reticent to give the informed consent or to comply with the study requirements.~3. Patients with glomerular filtration rate (GFR) less than 90 ml/min/1.73m2.~4. Portal hypertension: ascites, cirrhosis.~5. Medical records of total gastrectomy and/or vagotomy.~6. Patients diagnosed with myxedema.~7. Patients with Diabetes Mellitus.~8. Patients who are participating or have participated in any clinical trial within the 3 months previous to their inclusion in the study.~9. Patients who are drug abuse consumers.~10. Patients under treatment with antibiotics, sulphamides and antiparasitics, who cannot suspend the treatments 7 days prior to the performance of the hydrogen breath test.~11. Patients with any recognized and already existing disorder that might interfere with the any of the lactose intolerance diagnosis tests.~12. Patients who have taken aspirin of indomethacin in the 48h preceding the performance of the Gaxilose test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- LacTEST (Type: EXPERIMENTAL): 0,45 g of gaxilose po, once, per diagnostic test performed.
- Hydrogen Breath Test (Type: ACTIVE_COMPARATOR): 25 to 50 g of lactose po, once, per diagnostic test performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete